Introduction

- Studies that suggest that agents that modulate underlying neurochemical components of pruritus play a role in the treatment of chronic pruritus.
- These agents have all been generally appear well tolerated, with the most commonly reported AEs being insomnia and gastrointestinal effects.

Disclosures

- Financial support was received from: Trevi Therapeutics, Menlo Therapeutics, Abbvie, Janssen Pharmaceuticals, and Blistex Pharmaceuticals.
- M.R.K., D.S., and M.J.C. are employees of Trevi Therapeutics. M.R.K. is an advisory board member/scientific advisor for Trevi Therapeutics, Menlo Therapeutics, RAPT Therapeutics and Sanofi Pharmaceuticals. She is also an investigator for the PRISM trial by Trevi Therapeutics.